Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
12.41 (1y: -12%)
Market Cap 1.43 B P/E(ttm)
Enterprise Value 1.36 B P/B 9.20
IRWD- NAS (USA)
Ironwood Pharmaceuticals, Inc.
Not Rated
Top Ranked Predictable Companies
$12.41
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry		 vs
history
Cash to Debt 295.656
IRWD's Cash to Debt is ranked higher than
79% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.95 vs. IRWD: 295.656 )
IRWD' s 10-Year Cash to Debt Range
Min: 31.03   Max: 420.39
Current: 295.66
31.03
420.39
Equity to Asset 0.627
IRWD's Equity to Asset is ranked higher than
65% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. IRWD: 0.627 )
IRWD' s 10-Year Equity to Asset Range
Min: -1.86   Max: 0.63
Current: 0.63
-1.86
0.63
Interest Coverage No Debt
IRWD's Interest Coverage is ranked higher than
78% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.60 vs. IRWD: No Debt )
IRWD' s 10-Year Interest Coverage Range
Min: No Debt   Max: No Debt
Current: No Debt
F-Score: 3
Z-Score: 0.96
M-Score: -4.78
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry		 vs
history
Operating margin (%) -48.40
IRWD's Operating margin (%) is ranked lower than
55% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. IRWD: -48.40 )
IRWD' s 10-Year Operating margin (%) Range
Min: -550.6   Max: -48.4
Current: -48.4
-550.6
-48.4
Net-margin (%) -48.3
IRWD's Net-margin (%) is ranked lower than
55% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. IRWD: -48.3 )
IRWD' s 10-Year Net-margin (%) Range
Min: -504.1   Max: -48.3
Current: -48.3
-504.1
-48.3
ROE (%) -50.4
IRWD's ROE (%) is ranked lower than
58% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. IRWD: -50.4 )
IRWD' s 10-Year ROE (%) Range
Min: -59   Max: -33.2
Current: -50.4
-59
-33.2
ROA (%) -31.6
IRWD's ROA (%) is ranked lower than
56% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. IRWD: -31.6 )
IRWD' s 10-Year ROA (%) Range
Min: -43.8   Max: -17.6
Current: -31.6
-43.8
-17.6
Revenue Growth (%) -27.4
IRWD's Revenue Growth (%) is ranked lower than
64% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. IRWD: -27.4 )
IRWD' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 21.8
Current: -27.4
0
21.8
EBITDA Growth (%) -50.5
IRWD's EBITDA Growth (%) is ranked lower than
69% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. IRWD: -50.5 )
IRWD' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -5.8
Current: -50.5
EPS Growth (%) -48.9
IRWD's EPS Growth (%) is ranked lower than
70% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. IRWD: -48.9 )
IRWD' s 10-Year EPS Growth (%) Range
Min: 0   Max: -2.5
Current: -48.9
» IRWD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

IRWD Guru Trades in Q2 2012

Lee Ainslie 2,101,695 sh (unchged)
Vanguard Health Care Fund 2,000,000 sh (unchged)
Pioneer Investments Sold Out
» More
Q3 2012

IRWD Guru Trades in Q3 2012

Vanguard Health Care Fund 2,000,000 sh (unchged)
Lee Ainslie 2,101,695 sh (unchged)
» More
Q4 2012

IRWD Guru Trades in Q4 2012

Vanguard Health Care Fund 2,000,000 sh (unchged)
Lee Ainslie 2,101,695 sh (unchged)
» More
Q1 2013

IRWD Guru Trades in Q1 2013

Vanguard Health Care Fund 2,181,746 sh (+9.09%)
Lee Ainslie Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with IRWD

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Lee Ainslie 2013-03-31 Sold Out 0.34%$11.08 - $18.85 $ 12.41-16%0
Lee Ainslie 2011-06-30 Reduce -35.91%0.18%$14.02 - $16.4 $ 12.41-18%2171197
Lee Ainslie 2010-09-30 Add 309.79%0.3%$9.1 - $12.93 $ 12.4119%3647124
Vanguard Health Care Fund 2010-06-30 Sold Out 0.14%$9.89 - $14.78 $ 12.41-2%0
Vanguard Health Care Fund 2010-03-31 New Buy0.15%$11.5 - $14.63 $ 12.41-5%2000000
Lee Ainslie 2010-03-31 New Buy0.13%$11.5 - $14.63 $ 12.41-5%890000
Premium More recent guru trades are included for Premium Members only!!
» Financial Charts

Peter Lynch Chart

Ratios

vs
industry		 vs
history
P/B 9.20
IRWD's P/B is ranked lower than
61% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.42 vs. IRWD: 9.20 )
IRWD' s 10-Year P/B Range
Min: 3.98   Max: 34.91
Current: 9.2
3.98
34.91
P/S 9.46
IRWD's P/S is ranked lower than
57% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.59 vs. IRWD: 9.46 )
IRWD' s 10-Year P/S Range
Min: 2.51   Max: 34.77
Current: 9.46
2.51
34.77
EV-to-EBIT 5.3
IRWD's EV-to-EBIT is ranked higher than
88% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 16.29 vs. IRWD: 5.3 )
IRWD' s 10-Year EV-to-EBIT Range
Min: 19.5   Max: 28
Current: 5.3
19.5
28

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 16.3
IRWD's Price/Net Cash is ranked lower than
55% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 13.90 vs. IRWD: 16.3 )
IRWD' s 10-Year Price/Net Cash Range
Min: 8.8   Max: 18.4
Current: 16.3
8.8
18.4
Price/Net Current Asset Value 248.2
IRWD's Price/Net Current Asset Value is ranked lower than
95% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.30 vs. IRWD: 248.2 )
IRWD' s 10-Year Price/Net Current Asset Value Range
Min: 221.6   Max: 1197
Current: 248.2
221.6
1197
Price/Tangible Book 9.3
IRWD's Price/Tangible Book is ranked lower than
71% of the 123 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.40 vs. IRWD: 9.3 )
IRWD' s 10-Year Price/Tangible Book Range
Min: 5.8   Max: 10.9
Current: 9.3
5.8
10.9
Price/Median PS Value 0.6
IRWD's Price/Median PS Value is ranked higher than
91% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. IRWD: 0.6 )
IRWD' s 10-Year Price/Median PS Value Range
Min: 0.5   Max: 1.2
Current: 0.6
0.5
1.2

Business Description

Ironwood Pharmaceuticals, Inc. was incorporated in Delaware on January 5, 1998. On April 7, 2008, the Company changed its name from Microbia, Inc. to Ironwood Pharmaceuticals, Inc. The Company is an entrepreneurial pharmaceutical company that discovers, develops and intends to commercialize differentiated medicines that improve patients' lives. The Company currently operates its human therapeutics business segment- human therapeutics segment consists of the development and commercialization of its product candidates, including linaclotide. Prior to the sale of its interest in Microbia, it also operated in the biomanufacturing segment. Its biomanufacturing segment, which comprised a much smaller part of its business, consisted of its majority ownership interest in Microbia. The Company's human therapeutics segment represented 100% of its total assets at December 31, 2011 and 2010. The Company is subject to federal, state, city and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials.
Company Website
SEC Reports
Industry: Diagnostics & Research
Compare:
Traded in other countries:I76.Germany
» More Articles for IRWD

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: GDOT, VOCS, PES, IRWD, ABR Nov 11 2012 
Edward Owens Made Few Purchases In Times of Changes: Boston Scientific Corp., Ironwood Pharmaceutica May 10 2010 
Vanguard Health Care Fund Buys Ironwood Pharmaceuticals Inc., Johnson & Johnson, Boston Scientific C May 06 2010 

More From Our Partners
IRWD Launches Constella in Europe - Analyst Blog Jun 17 2013 - ZACKS

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK